Abstract
Amoebiasis is a ubiquitous disease caused by the protozoan parasite Entamoeba histolytica. It infects 50 million people per year and leading cause of death about 100,000 people due to parasitic disease worldwide. Metronidazole is the primary treatment for amoebiasis. The feature of this disease is the occurrence of morbidity affecting the quality of life and the pace of developmental activities. The adequate therapy for amoebic colitis is necessary to reduce illness, prevent development of complicated disease and extraintestinal spread, and decrease transmission. There are number of agents which possess potent amoebicidal action against trophozoites of E. histolytica available for therapeutic use. So, the prompt possessing symptomatic relief of suffering is from intestinal dysentery. Metronidazole is one of the most effective antiamoebic medications. However, we are in need of new drugs to inhibit the growth of Entamoeba histolytica. Hence, the present protocol is used to screen the antiamoebic activity of actinobacteria isolates.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Stanley SL (2001) Pathophysiology of amoebiasis. Trends Parasitol 17(6):208–285
Tona L, Kambu K, Ngimbi N, Cimanga K, Vlietinck AJ (1998) Antiamoebic and phytochemical screening of some Congolese medicinal plants. J Ethnopharmacol 61:57–65
Espinosa A, Socha AM, Ryke E, Rowley DC (2012) Antiamoebic properties of the actinomycete metabolites echinomycin A and tirandamycin A. Parasitol Res 111:2473–2477
Ganesh Kumar C, Himabindu M, Jetty A (2008) Microbial biosynthesis and applications of gentamicin: -a critical appraisal. Crit Rev Biotechnol 28(3):173–212
Cartuche L, Reyes-Batlle M, Sifaoui I, Arberas-Jiménez I, Piñer JE, Fernández JJ, Lorenzo-Morales J, Díaz-Marrero AR (2019) Antiamoebic activities of indolocarbazole metabolites isolated from Streptomyces sanyensis cultures. Mar Drugs 17(10):588
Bharti N, Maurya MR, Naqvia, F. &Azama. A. (2000) Synthesis and antiamoebic activity of new cyclooctadiene ruthenium(II) complexes with 2-acetylpyridine and benzimidazole derivatives. Bioorg Med Chem Lett 10:2243–2245
Abid M, Azam A (2006) Synthesis, characterization and antiamoebic activity of1-(thiazolo[4,5-b]quinoxaline-2-yl)-3-phenyl-2-pyrazoline derivatives. Bioorg Med Chem Lett 16:2812–2816
Hayat F, Salahuddin A, Umar S, Azam A (2010) Synthesis, characterization, antiamoebic activity and cytotoxicity of novel series of pyrazoline derivatives bearing quinoline tail. Eur J Med Chem 45:4669–4675
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2022 The Author(s), under exclusive license to Springer Science+Business Media, LLC, part of Springer Nature
About this protocol
Cite this protocol
Balakrishnan, K., Dharumadurai, D., Ramasamy, T., Manickam, M. (2022). An In Vitro Antiamoebic Activity of Actinobacteria. In: Dharumadurai, D. (eds) Methods in Actinobacteriology. Springer Protocols Handbooks. Humana, New York, NY. https://doi.org/10.1007/978-1-0716-1728-1_52
Download citation
DOI: https://doi.org/10.1007/978-1-0716-1728-1_52
Published:
Publisher Name: Humana, New York, NY
Print ISBN: 978-1-0716-1727-4
Online ISBN: 978-1-0716-1728-1
eBook Packages: Springer Protocols